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GENERATION OF BOTH AN shRNA-RESISTANT MEF2A OVER 
EXPRESSION CONSTRUCT AND A DOMINANT NEGATIVE MEF2 
CONSTRUCT IN ADENOVIRUS FOR RESCUE AND KNOCKOUT 
EXPERIMENTS IN MUSCLE 
KATHRYN COMEAU 
ABSTRACT 
The Myocyte Enhancer Factor-2, or MEF2, transcription factor family is necessary for 
the differentiation and regeneration of both skeletal and cardiac muscle tissue. The 
transcription factors in this family are responsible for the activation of many muscle 
specific growth factor-induced and differentiation genes.  There are four individual 
isoforms of MEF2; MEF2A, -B, -C, and –D, and the roles of these individual 
transcription factors are not completely understood.  Knockdowns of these individual 
isoforms revealed that a MEF2A knockdown mouse model displays severe myofibrillar 
defects in cardiac muscle.  This knockdown also has shown that MEF2A is required for 
myogenesis in vitro, where the other 3 isoforms, -B, -C, and –D, are not necessary for 
this process.   One method of knocking down MEF2A to study its roles further is through 
the use of short hairpin RNAs (shRNA).  The purpose of my research was two-fold.  
First, in order to test the specificity of this shRNA method, an shRNA-resistant MEF2A 
over expression construct in an adenoviral vector was created to perform rescue 
experiments.  Second, to compare individual MEF2 isoform knockouts to a complete 
knockout of the entire MEF2 family, a dominant negative construct was created in an 
adenoviral vector.  In both cases, a pShuttle-CMV adenoviral vector was used.   The 
 v
results of this experiment can be used to further investigate the roles of MEF2A in both 
regeneration and differentiation of skeletal and cardiac muscle tissue.   
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CHAPTER 1: Introduction 
1.1 Introduction 
     This thesis focuses on the roles of the MEF2 transcription factor family within 
mammalian cardiac and skeletal muscle.  This family is composed of four MEF2 
isoforms; MEF2A, -B, -C, and –D.  There is a high level of conservation between 
each isoform, however they all have distinct roles in the development of muscle.  
This work specifically focuses on the MEF2A isoform, which has been shown to 
be necessary for myogenesis in vitro.  The purpose of this study has two parts.  
The first is to create an shRNA-resistant MEF2A over expression construct in an 
adenoviral vector to use in rescue experiments in order to determine the 
specificity of the MEF2A knockdown using an shRNA method.  The second is to 
create a dominant-negative MEF2 construct in adenovirus to compare knockouts 
of individual isoforms to the knockout of the entire MEF2 family.   
1.2 Development and Differentiation of Striated Muscle  
1.2.1 Mammalian Myogenesis 
     Myogenesis is the process by which mammalian muscle is formed, and it 
involves the differentiation of muscle precursor cells into mature myocytes.  This 
process happens not only during the development of the embryo, but also in adult 
muscle regeneration.  Gastrulation takes place during embryogenesis, at 
embryonic day 7 (E7) in mice, which forms the ectoderm, endoderm, and 
mesoderm (Mok and Sweetman 2010).   A specific population of cells is 
separated from the newly formed mesoderm for the formation of both the cardiac 
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and skeletal muscle tissue.   
     Both cardiac and skeletal muscles are forms of striated tissue.  They are given 
this name due to their striated pattern of the contractile subunits, or sarcomeres.  
The sarcomeres consist of actin and myosin filaments that move against each 
other to lengthen or shorten a muscle (Figure 1.1).  The Z-disc is what links each 
sarcomere to its adjacent partner, which produces the aforementioned striated 
pattern within the larger contractile units, called myofibrils.  Many myofibrils 
bundled together form each myofiber, which is a single multi-nucleated muscle 
cell (Braun and Gautel 2011).   
     The pathways for both cardiac and skeletal muscle myogenesis involve the 
same small set of signaling molecules and transcription factors.  Signaling 
cascades involving Wnt, FGF, and BMP provide not only cues involving 
positioning, but also differentiation and proliferation signals to the myogenic 
precursor cells (Yokoyama and Asahara, 2011).   Cardiac and skeletal muscle also 
each use MEF2 transcription factors to help in the development of mature 
myocytes.   
1.2.2 Cardiac Muscle Development  
     As the embryo develops, the first mesodermal tissue to differentiate after 
gastrulation is the heart.  The development of heart muscle begins at about E7.5 in 
mice, as is indicated by the expression of BMPs, Wnt inhibitors, and fibroblast 
growth factor 8, which work together to aid in the making of progenitor cells in 
the mesoderm (Marvin, Di Rocco et al., 2001).  A segregated population of cells 
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that arises from the newly formed mesoderm migrates under the head folds to 
form the cardiac crescent, which initiates the formation of the heart.  This 
activates a network of cardiac-specific transcription factors, including the MEF2A 
family of proteins (Harvey, Lai et al., 2002).  A bit later in development, at about 
E8.25, the linear heart tube is formed.  This is made up of an inner endothelial 
layer surrounded by a layer of myocardial cells.  This tube goes through a 
complex rightward looping process, followed by the formation of the atria, 
ventricles, and valves, which can be seen by E10.5.  The functional heart, which 
includes all four chambers, pulmonary arteries, and the aorta, is formed by E12.5 
(Zheng, Wen et al., 2003).  Cardiac malformations can occur with a loss of 
function of many transcription factors that are present during this process, 
including the MEF2A family.   
1.2.3  Skeletal Muscle Development  
     Skeletal muscle is a contractile structure that is composed of multiple layers 
that is designed for both controlled and voluntary movement.  Bundles of 
myofibers are combined together to make up the muscle groups of this tissue.  
The myofibers each have multiple nuclei just beneath the sarcolemma, and just 
outside of the sarcolemma lies a population of satellite cells.  Satellite cells are 
muscle specific stem cells that are involved in both the repair and homeostasis of 
the muscle.  All of these cells work together to regenerate whole muscle in 
response to injury.   
     A short time after gastrulation occurs, somites, which are mesodermal cells 
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that are positioned next to the notochord and neural tube, give rise to the dorsal 
dermomyotome from which the skeletal muscle will form.  The specification of 
the myogenic progenitor cells in the dermomyotome begins with the expression of 
paired homeobox transcription factors (Pax) 3 and 7, which are triggered by Wnt, 
BMP, and SHH signals from the surrounding tissues.  The cells that are positive 
for Pax3 will migrate from the dermomyotome to form the myotome (Mok and 
Sweetman, 2010).   
     Differentiation within the myotome starts with the down regulation of Pax3, 
followed by an exit from the cell cycle and the expression of myogenic regulatory 
factors (MRF) such as Myf5, MyoD, and myogenin (Figure 1.2) (Mok and 
Sweetman, 2010).  MEF2 factors are also expressed.  Loss-of-function 
experiments have shown that several of these transcription factors are important 
for the development of skeletal muscle.  Once the cells leave the cell cycle, 
myogenin will kick off the differentiation of myoblasts into mature muscle.  Cells 
that express Pax3 and Pax7 from the dermomyotome at this stage are important 
for the specification of myogenic progenitor cells that will form the adult satellite 
cells (Mok and Sweetman, 2010).   
1.3 Myocyte Enhancer Factor-2 Transcription Factors 
1.3.1 Identification and Structure of MEF2 
     Myocyte enhancer factor-2 (MEF2) proteins are part of the MADS-box 
superfamily of transcription factors.  These proteins were originally identified as a 
nuclear factor in skeletal myocytes that bound to a conserved sequence that is A/T 
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rich, located within the muscle creatine kinase (mck) promoter.  MEF2 was 
expressed before MCK in differentiated myotubes, so this factor was designated 
as an early molecular marker of muscle differentiation (Gossett, Kelvin et al., 
1989).  Since its discovery, MEF2 binding sites have also been identified in many 
control regions of muscle specific genes.  Because of this, MEF2 has been 
recognized as a regulator of muscle development.  There are four known genes 
that belong to the MEF2 family in mammals; MEF2A, -B, -C, and –D, and they 
are located on four different chromosomes (Cripps and Olson, 2002).  In contrast, 
Drosophila and C. elegans have only one MEF2 gene that encodes D-MEF2 and 
CeMEF2, while Xenopus has two MEF genes designated Xmef2a an Xmef2d  
(Dichoso, Brodigan et al., 2000; Wong, Pisegna et al., 1994).   
     The N-terminal regions of MEF2 factors are highly conserved, containing a 
MADS-box domain and an adjacent MEF2 domain, while the C-terminal regions 
have little to no homology (Figure 1.3).  The MADS-box is a 57-aa motif, and this 
family of proteins is named after the first four members that were identified 
(MCM1, Agamous, Deficiens, and SRF) (Shore and Sharrocks, 2005). The 
MADS-box domain and the MEF2 domain work together to mediate dimerization 
and DNA binding, and they are necessary for co-factor interactions of some 
MEF2 proteins (Molkentin, Black et al., 1995).  MEF2 factors can homo- and 
heterodimerize with each other through this domain, but they cannot form 
heterodimers with other MADS-box family members.  They also can bind the 
DNA consensus sequence YTA(A/T)4TAR (Pollock and Treisman, 1991).  The 
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factors in the MEF2 family share about 50% aa identity overall, and there is 95% 
similarity between the MADS and MEF2 domains.  There is a transactivation 
domain located in the C-terminal region that is highly variable and is subject to 
alternative splicing, which produce some muscle and neuronal specific isoforms 
(Breitbart, Smoot et al., 1992; Breitbart, Liang et al., 1993).   
1.3.2 MEF2 Gene Expression  
     The patterns of expression for MEF2 transcripts are distinct but overlapping in 
both embryonic development and adult muscle tissues.  The expression of MEF2 
proteins in chondrocytes, neurons, and muscle occurs together with the onset of 
their differentiation during embryogenesis.  Throughout the development of the 
embryo and into adulthood, MEF2 expression is highest in the cardiac and 
skeletal muscle (Potthoff and Olson, 2007).   
     Mef2b and Mef2c mRNAs are the first to be detected during development at 
E7.5 in the cardiac mesoderm of mouse embryos, and in the skeletal 
dermomyotome at E8.5.  Mef2a and Mef2d are detected in the myocardium by 
E8.5 and are expressed in the heart throughout development and into adulthood 
(Edmonson, Lyons et al., 1994; Molkentin and Olson, 2002).  The expression of 
Mef2b and –c begins to decline around E10.5 and they are undetectable post 
E13.5.  The expression pattern of MEF2 transcripts is similar in skeletal muscle, 
where Mef2c is detected at around E8.5, and the expression of Mef2b follows at 
E9.0 (Figure 1.4).  Beginning at E9.5, Mef2a and Mef2d are detectable and are 
expressed throughout the development of skeletal muscle and into adulthood.  In 
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contrast to cardiac muscle development, Mef2b and –c continue to be expressed in 
skeletal muscle through development and after birth (Edmonson, Lyons et al., 
1994; Molkentin and Olson, 2002).  There are several skeletal muscle lineage 
markers and structural genes that are expressed prior to Mef2, and this suggests 
that these markers may initiate the expression of Mef2 in skeletal muscle.  Several 
studies suggesting that MEF2A activates myogenin have also shown that MEF2A, 
-B, and –D are expressed in myoblasts before the expression of this gene 
(Breitbart, Liang et al., 1993).  MEF2 transcripts are also detected in smooth 
muscle, the central nervous system, and cartilaginous tissue, starting in the late 
stages of development and continuing into adulthood (Edmonson, Lyons et al., 
1994).   
1.3.3 MEF2 Regulation 
1.3.3.1 Transcriptional Control 
     MEF2 factors are responsible for regulating a large array of developmental 
programs such as differentiation, cell division, and cell death (Potthoff and Olson, 
2007).  Mutually exclusive cues are necessary for a cell to make the decision to 
divide or die, and this is highly regulated.  Because of their strong regulating 
roles, MEF2 factors are subject to strict and complex regulation at the 
translational and post-translational levels through interactions with both activators 
and repressors (McKinsey, Zhang et al., 2002).  In mammals, the Mef2 genes have 
long 5’ untranslated regions (UTR), which undergo alternative splicing.  This 
makes it hard to study the control of these genes at the transcriptional level.  Mef2 
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enhancers have been identified and characterized in Drosophila.  In this model, at 
least 12 separate enhancers exist in the 12 kbp upstream of D-mef2, and the direct 
transcription of D-mef2 is in a temporospatial pattern (Black and Olson, 1998).  
The regulatory regions upstream of Mef2a and Mef2c in mammals have only been 
partially characterized.  To regulate transcription, the 5’ UTR regions of 
mammalian Mef2 genes have regulatory regions that will bind to myogenic bHLH 
and proteins belonging to the MEF2 family.  In addition, Mef2A is a 
transcriptional target of nuclear respiratory factor 1 (NRF1) (Ramachandram, Yu 
et al., 2008).  Because of the complexity of the regulation patterns, no regulatory 
regions have been identified for Mef2b or –d.  These findings support the idea that 
the regulation of the expression of MEF2 occurs at the transcriptional level, and 
therefore it can be said that transcriptional regulation can account for the 
overlapping but distinct temporal expression patterns of mammalian MEF2 
transcripts.   
1.3.3.2 Translational Control 
     With the exception of Mef2c, whose expression is limited to the brain, spleen 
and skeletal muscle, the expression of MEF2 transcripts is ubiquitous (Pollock 
and Treisman, 1991).  The protein expression of MEF2 transcripts, however, is 
restricted to striated muscle and the brain due to translational control (Breitbart, 
Liang et al., 1993).  Studies have shown that microRNAs regulate the expression 
of transcription factors that are important for the development of both cardiac and 
skeletal muscle (Small and Olson, 2011).  In the 3’ UTR region of Mef2a, there is 
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an evolutionarily conserved sequence, which inhibits the expression of any 
MEF2A proteins in anything but muscle cells.  The binding of miR-155 to the 3’ 
UTR of MEF2A prevents translation, and therefore inhibits the differentiation of 
skeletal myoblasts.   
1.3.3.3 Post-translational Control 
    Repressive complexes at MEF2-dependent gene regulatory regions are formed 
by histone deacetylases (HDACs) to inhibit the transcriptional activity.  Class II 
HDACs 4, 5, 7, and 9 are associated with DNA-bound MEF2 proteins and 
deacetylate histones to repress the expression of the genes.  The phosphorylation 
of HDACs is caused by an increase of intracellular calcium, and this creates 
docking site for 14-3-3, which will disrupt the interactions between the HDACs 
and MEF2 proteins, and it masks the HDAC nuclear localization signal (NLS).  
After this, HDAC is removed from the nucleus so that the transcription of MEF2-
dependent genes can occur.  The activity of MEF2D can also be stimulated by the 
direct interaction of 14-3-3 with the MADS/MEF2 domains (McKinsey, Zhang et 
al., 2002).  It is assumed that the post-translational control of MEF2 occurs 
through mechanisms other than this HDAC path due to the fact that Class II 
HDACs are mainly expressed in the brain, heart, and skeletal muscle.   
     Both the p38 and ERK/MAPK pathways phosphorylate MEF2, which leads to 
an increase in the transcriptional activity of MEF2.  This in turn promotes 
differentiation and cell growth.  MEF2D is activated by p38 by the direct 
phosphorylation of the MADS/MEF2 domain.  This activated MEF2D will 
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interact with MyoD and activate the expression of late myogenic markers.  MEF2 
proteins regulate a large amount of developmental programs by interacting with 
many transcription factors.  This allows the MEF2 binding partners to modulate 
the MEF2 activity (Black and Olson, 1998).   
1.3.4 Loss-of-Function and Gain-of-Function Models for MEF2 Factors 
1.3.4.1 Invertebrate MEF2 Loss-of-Function 
     Two mutations were created to determine the function of CeMef2 in C. 
elegans.  The first mutation deleted the MADS box and MEF2 domain and it was 
considered a null allele.  The second mutation deleted a sequence in the 3’ region 
of the gene, and this gene made a product but it was missing 167 amino acids in 
the C-terminal protein.  The results from these experiments showed that CeMef2 
is not required for the development of muscle in C. elegans and the mutants do 
not have a strong visible phenotype or defects during myogenesis.  As adults, the 
CeMef2 mutants are shorter than the wild type, which suggests that MEF2 has a 
different pathway other than muscle development in C. elegans (Shore and 
Sharrocks, 2005).  These results suggest that CeMef2 has developed an 
evolutionarily divergent role in respect to myogenesis, or its ability to regulate the 
differentiation of muscle has been replaced by another transcription factor. 
     D-mef2, the MEF2 gene in Drosophila, is primarily expressed in the mesoderm 
and muscle cell types.  A null mutation of D-mef2 in Drosophila produces flies 
that do not develop differentiated muscle and die during embryogenesis (Bour, 
O’Brien et al., 1995).  This indicates a crucial role for this MEF2 protein in 
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myogenesis and muscle differentiation.   
1.3.4.2 MEF2A 
     Mice that lacked both mef2a alleles (mef2a-/-) were created using homologous 
recombination embryonic stem (ES) cells.  These knockout mice suffer from 
perinatal lethality and sudden death from severe cardiac cyto-architectural defects 
that include myofibrillar disorganization, right ventricular chamber dilation, and 
random mitochondria distribution.  Microarray analyses using cardiac RNA show 
that structural, mitochondrial, and stress-responsive genes are dysregulated in 
these mef2a-/- mutants, and their gene programs resemble one that is characteristic 
of cardiac failure.  These mice show no skeletal muscle defects at the histological 
level (Naya, Black et al., 2002).  ChIP-chip analyses did show that MEF2A 
associates with a variety of promoters whose genes are known to be important in 
the process of muscle differentiation and function (Paris, Virtanen et al., 2004).  
Skeletal muscle regeneration, however, is impaired in adult mice without MEF2A 
due to abnormal Wnt signaling (Snyder, Rice et al., 2012).  Differentiation is not 
impaired in MEF2A knockouts targeted to the adult satellite cells in the context of 
muscle injury, however it is perturbed when MEF2A, -C, and –D are deleted 
simultaneously (Liu, Nelson et al., 2013).  A dominant-negative form of MEF2A 
that lacks a transcriptional activation domain inhibits the formation of myotubes 
and also the expression of important muscle regulatory genes.  The expression of 
this dominant-negative MEF2A in C3H10T1/2 fibroblasts impairs MyoD 
mediated myogenic conversion.  This result suggests that MEF2A is necessary for 
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muscle specific gene expression and myogenesis (Ornatsky, Andreucci et al., 
1997).   
     Overexpession studies of mef2a in the heart have shown that careful 
modulation of the expression level of this gene is necessary for this muscle to 
function properly.  Transgenic mice overexpressing mef2a displayed a thinning of 
ventricular walls, ventricular chamber dilation, and a MEF2A dose-dependent 
activation of the fetal gene program (van Oort, Rooij et al., 2006).  The 
overexpression of MEF2A in cultured neonatal rat cardiomyocytes (NRCs) is 
sufficient to dysregulate expression of α-myosin heavy chain (α-MHC) and α-
actinin, two structural proteins associated with the sarcomere.  Other proteins 
related to ion channels, adhesion, and the extracellular matrix, were also 
dysregulated (Xu, Gong et al., 2006).   
1.3.4.3 MEF2B 
     The expression of mef2b is in line with the expression of mef2c in cardiac 
muscle cells and lags slightly behind mef2c in skeletal muscle lineages of the 
developing embryo (Molkentin, Lu et al., 1998).  MEF2B is known to bind to the 
MEF2 consensus sequence along with forming a heterodimeric complex with E12 
and myogenin to bind to and activate regulatory regions of target genes 
(Molkentin and Olson, 1996).  According to research demonstrated by Black et al. 
(1998), MEF2B null mice are viable with no obvious phenotype.  As myogenesis 
proceeds beyond the early differentiation stages, MEF2B is expressed at its 
highest levels in the ends of myofibers and myotubes.  This indicates a possible 
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role for MEF2B in the fusion of the myotubes with the ends of the myofibers 
(Molkentin, Lu et al., 1998). 
1.3.4.4 MEF2C 
     MEF2C is the earliest factor expressed during development of the mouse 
embryo (Molkentin and Olson, 1996).  A MEF2C knockout caused mice to die 
prenatally due to defects during the heart looping process, and this results in a 
failure to form the future right ventricle (Lin, Schwarz et al., 1997).  Genes such 
as α-MHC and α-actinin fail to be expressed, which impairs circulation, 
worsening the morphogenic heart defects that are observed (Lin, Schwarz et al., 
1997).  MEF2C null embryos fail to form vascular systems and have 
disorganization in the assembly of endothelial cells (Lin, Lu et al., 1998).  A 
conditional skeletal muscle MEF2C knockout was used to show that MEF2C null 
skeletal muscle quickly degenerates perinatally, the integrity of the sarcomeres is 
compromised, and its function is impaired (Potthoff and Olson, 2007).   
     Overexpression of MEF2C in the p19 cardiac cell line supports the cardiac 
phenotype that was seen in MEF2C null mice.  In this model, MEF2C is sufficient 
to induce cardiomyogenesis.   This overexpression upregulates the expression of 
Bmp4, Nkx2-5, Gata4, cardiac α-actinin, and MHC, and this is sufficient to direct 
the early stages of differentiation in cardiomyocytes (Skerjanc, Petropoulos et al., 
1998).  
     Together, the aforementioned studies suggest a possible conserved role for 
MEF2C in the maintenance and assembly of the heart and vascular systems, along 
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with being required for the proper assembly and maintenance of sarcomeres.  
Additionally, studies have shown that MEF2C could be active in the precardiac 
mesoderm and could act redundantly to ensure proper differentiation of striated 
muscle.   
1.3.4.5 MEF2D 
     The expression of mef2d in the developing mouse is expressed in the same 
temporal pattern as mef2a in both cardiac myocytes and the developing somite 
myotome, and these are the predominant MEF2 isoforms that are expressed in 
adult cardiomyocytes.  This suggests a dual role for MEF2D in both the 
development and maintenance of mature muscle (Edmonson, Lyons et al., 1994; 
Naya, Black et al., 2002).  Loss- and gain-of-function studies have been done with 
MEF2D in both cardiac and skeletal muscle to investigate its function further.   
     Mef2d-/- knockout mice are viable with no histological abnormalities in a range 
of tissue types, including cardiac and skeletal muscle.  These mice do, however, 
display a blunted response to cardiac stress due to pressure overload, which 
included a resistance to cardiac remodeling and fibrosis when compared to the 
wild type mice (Kim, Phan et al., 2008).  Overexpression of MEF2D in transgenic 
mice resulted in hearts that were sufficient in activating both fibrosis and 
hypertrophy (Kim, Phan et al., 2008). MEF2D overexpression also results in a 
distinct cardiac phenotype since the overexpression of MEF2A of MEF2C results 
in dilated cardiomyophathy with little to no hypertrophy (Xu, Gong et al., 2006).  
This suggests a unique set of genes that MEF2D may target.    
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     Analysis of skeletal muscle MEF2D null mice showed no obvious histological 
abnormalities (Kim, Phan et al., 2008).  The conditional deletion of mef2d in 
skeletal muscle did, however, indicate a role for MEF2D in the activation of slow, 
oxidative-fiber type muscle genes.  This is because the activity-dependent ability 
of muscle cells to make a fast- to slow-fiber type transformation is lost when 
mef2c or mef2d is deleted in skeletal muscle (Potthoff and Olson, 2007).  A study 
that used a morpholino knockdown of MEF2C and MEF2D in zebrafish skeletal 
muscle showed a need for these two factors in the expression of thick filament 
contractile proteins that are necessary for the proper assembly of sarcomeres 
(Hinits and Hughes, 2007).  The studies mentioned above suggest a role for 
MEF2D in the activation of specific muscle contractile proteins in the adult 
striated muscle in response to pathological or physiological cell stress.  Further 
investigation is needed to determine the precise role of MEF2D in striated muscle. 
1.4 Short Hairpin RNA 
     RNA interference (RNAi) is a biological response to exogenous double-
stranded RNA (dsRNA) that was first discovered in C. elegans, and this response 
induces a sequence-specific form of gene silencing.  The regulatory motif of 
RNAi is conserved across a wide range of eukaryotic organisms, and 
endogenously encoded triggers of gene silencing can work through elements of 
this machinery to in turn regulate the expression of genes that code for specific 
proteins.  Small temporal RNAs are transcribed as short hairpin precursors that 
are 17 nucleotides long, and they are processed into active, 21 nucleotide long 
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strands of RNA by Dicer (Figure 1.5).  These strands then recognize and target 
specific mRNAs based on interactions between base pairs (Paddison, Caudy et al., 
2002).  Paddison et al. (2002), among others, showed that short hairpin RNAs 
(shRNAs) can be created to knock down the expression of certain desired genes in 
mammalian cells by using this specific base-pairing interaction method.  By using 
shRNAs to suppress the expression of genes, we can further understand gene 
programs.  In the case of this thesis, shRNA can be used to acutely knock down 
each MEF2 member to study the phenotypes created by these mutants and 
therefore learn more about the function of each MEF2 member.   
1.5 Statement of Thesis Rationale 
     The focus of my thesis is two-fold.  The first goal is to generate an shRNA 
resistant MEF2A construct in an adenoviral vector to use for rescue experiments 
in both cardiac and skeletal muscle.  Although the shRNA method of suppressing 
genes is sequence specific, we do not know if these strands of RNA have other 
off-site targets that could create the phenotypes observed.  The generation of this 
construct would allow us to over express the shRNA resistant form to demonstrate 
that we can rescue the phenotype in cardiac and skeletal muscles caused by the 
knockdown of MEF2A to show the shRNA method’s specificity.  If there is a 
strong rescue, we can say that the shRNA used to knockdown MEF2A is specific 
for that gene and not targeting any others.  If there is no rescue at all, it implies 
that the shRNA is targeting a gene other than MEF2A that is causing the observed 
phenotype.  If there is an incomplete rescue with the overexpression of the 
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shRNA resistant form of MEF2A, it could suggest that the shRNA is targeting 
both MEF2A and other off target genes to produce the observed phenotypes.   
     The second focus of this thesis is to create a dominant negative MEF2 
construct in an adenoviral vector.  This can be used to knock out all members of 
the MEF2 transcription factor family at once as opposed to knocking down each 
factor separately.  This could allow us to observe what happens to the specific 
gene programs that involve all members of the MEF2 family.  
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Figure 1.1 The contractile unit of striated muscle: the sarcomere.  Schematic showing 
the cross-striations of a skeletal myocyte (left) and a cardiomyocyte (right).  The 
sarcomere is composed of antiparallel filaments of actin and myosin.  This image shows 
the pattern created by the Z-disc regions in each sarcomere that line up end to end in the 
myofibrils (Adapted from Braun and Gautel, 2011). 
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Figure 1.2 Schematic of satellite cell myogenesis.  Satellite cells are quiescent in 
normal muscle but can be activated by things such as muscle damage.  When activated, 
they divide to produce myoblasts that will proliferate and fuse to form myotubes, which 
will then form myofibers.  The activation of satellite cells is marked by expression of 
myogenic regulatory factors such as Myf5, MyoD, and myogenin (Zammit et al., 2006). 
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Figure 1.3 The sequences of the Myocyte Enhancer Factor 2 transcription factor 
family are conserved.  The MEF2 transcription factor family is evolutionarily 
conserved.  The proteins in this family share approximately 95% similarity within the 
MADS box and MEF2 domains (Potthoff and Olson, 2007).  
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Figure 1.4 MEF2 Temporal expression during muscle development.  The pattern of 
cardiac muscle expression is shown in black, and a similar expression in skeletal muscle 
is shown in red, approximately one day later.  MEF2 is detected as early as E7.5 in the 
heart, and E8.5 in skeletal muscle (Edmondson et al., 1994).   
 
 
 22
 
 
 
 
 
Figure 1.5 shRNA processing schematic.  The path by which shRNA is processed in 
order to be used to bind to the target mRNA sequence so that the desired strand of mRNA 
can be cleaved.  This process is used in knockdown experiments (De Rienzo, et al., 
2012).   
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CHAPTER 2: Materials and Methods 
2.1     Preparation of the MEF2A-FLAG Insert 
                A double digestion of the shRNA-resistant MEF2A plasmid in a pCDNA3 
vector was performed using KpnI and NotI.  1 µL (1 µg) of the shRNA-resistant 
MEF2A plasmid (stored at -20oC), 0.5 µL of Kpn1, 0.5 µL of Not1, 2 µL of Buffer 
2.1, and 16 µL of dH2O were added to a 1.5 mL microfuge tube to reach a final 
volume of 20 µL.  The tube was Parafilmed and placed in a 37oC water bath for 1 
h.  Once the incubation was complete, the digested plasmid was stored at -20oC.  
The restriction enzymes and buffer were purchased from New England Biolabs 
(NEB) (Ipswich, MA) and were stored at -20oC.   
2.2     Preparation of the pShuttle-CMV Vector 
     A double digestion of the pShuttle-CMV vector was performed using KpnI and 
NotI.  1 µL (1 µg) of the pShuttle-CMV vector (stored at -20oC), 0.5 µL of Kpn1, 
0.5 µL of Not1, 2 µL of Buffer 2.1, and 16 µL of dH2O were added to a 1.5 mL 
microfuge tube to reach a final volume of 20 µL.  The tube was Parafilmed and 
placed in a 37oC water bath for 1 h.  Once the incubation was complete, the 
digested plasmid was stored at -20oC.   
2.3     Gel Purification and Extraction  
     The digested pShuttle-CMV vector and shRNA-resistant MEF2A insert, along 
with the undigested vector and insert, were electrophoresed on a 0.8% agarose gel 
containing ethidium bromide and visualized with UV.  The digested products were 
excised and gel extracted with the QIAquick gel extraction kit (QIAGEN) 
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according to manufacturer’s instruction.  The extracted products were stored at      
-20oC.   
2.4     Ligation Reaction and Transformation 
     15 µL of the extracted insert were added to 10 µL of the extracted vector, along 
with 1 µL of T4 DNA ligase and 4 µL of 10X T4 buffer (New England Biolabs).  
The solution was incubated at 16oC for 4 h and then stored at 4oC.   
     20 µL of thawed DH5α cells were combined with 10 µL of the ligation reaction 
and the solution was incubated over night at 37oC.  The cells were plated on pre-
warmed LB plates with ampicillin (100 µg/mL), sealed with Parafilm, and 
incubated upside-down for 16-18 h at 37oC.   
2.5     Mini-preps of Selected Colonies 
     Three solutions were made for this procedure.  Solution 1, a resuspension 
buffer, contained 50 mM glucose, 10 mM EDTA (pH 8.0), and 25 mM of Tris (pH 
8.0).  Solution 2, a lysis solution, contained 0.2 M NaOH and 1% SDS.  Solution 3, 
a neutralization buffer, contained 29.4 g Kac (3 M final concentration), 11.5 mL 
Acetic Acid, and brought up to 100 mL final volume with dH2O.   
     25 colonies were selected for mini-preps and inoculated in 3 mL of LB-
ampicillin (100 µg/mL) overnight.  1.5 mL were transferred to a microfuge tube 
and spun at 14000 rpm for 30 sec.  The supernatant was aspirated and the pellet 
was resuspended in 100 µL of solution 1.  200 µL of solution 2 was added and 
mixed by inversion and then incubated for 4 min at room temperature.  150 µL of 
solution 3 was added and mixed by inversion and 400 µL of phenol/chloroform 
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was added and the solution was vortexed and spun at 14000 rpm for 1 min.  400 
µL of the upper phase was transferred to a new tube containing 1 mL of cold 100% 
EtOH.  The solution was spun at 14000 rpm for 5 min and the supernatant was 
aspirated and the pellet was left to air dry at room temperature for 15 min.  Once 
dry, the pellet was resuspended in 20 µL of RNase water (100 µg/mL) and stored 
at -20oC.   
     This procedure was completed for both the shRNA-resistant MEF2A construct 
(MEF2A-FLAG) as well as the dominant negative form of MEF2 (MEF2-En).  A 
double digestion of the mini-preps for the dominant negative MEF2 was performed 
with BamH1 and Not1 using buffer 3.1 (New England Biolabs) to see if the 
insertion was successful.   
 
CHAPTER 3: Results and Discussion 
3.1     Preparation of the shRNA-resistant MEF2A Insert and pShuttle-CMV Vector 
     In order to achieve high level expression of the shRNA resistant form of 
MEF2A, one approach is to clone this expression construct in adenovirus. A 
number of cells lines are efficiently transduced by adenoviruses and high levels of 
expression can be achieved.  To begin, shRNA-resistant MEF2A and the pShuttle-
CMV plasmids that were used to create the overexpression construct in this 
experiment were digested with the restriction enzymes NotI and KpnI.  The 
products from the digestion were run on a 0.8% agarose gel to make sure that the 
plasmids were appropriately digested in preparation for the ligation reaction.  The 
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first three times that the restriction enzyme digestion and subsequent agarose gels 
were completed and visualized with UV, the bands shown for the digested insert 
and vector were no different than the control bands of the undigested vector and 
insert.  After the first two unsuccessful times of incubating the digestion reaction 
for one hour, the incubation time was increased to overnight.  Once the third 
digestion reaction was also unsuccessful, a new stock of the enzyme Not1 was 
ordered so as to make sure the enzyme had not lost its function.  The fourth time 
the experiment was performed, the gel displayed both the insert and the vector 
having the appropriate bands, indicating the desired digestion had occurred.   
3.2     Ligation Reaction and Transformation 
     After the restriction enzyme digestion, the desired fragments of the digested 
plasmids are combined to create the desired adenoviral vector. A ligation reaction 
between the shRNA-resistant MEF2A and the pShuttle-CMV insert was performed 
and combined with thawed DH5α cells.  The cells were plated on plates containing 
LB agar and Ampicillin.  This procedure was completed twice.  The first was 
unsuccessful, as no colonies grew on the plate, so new plates were prepared to 
ensure that there were no issues with the medium on which the cells were grown 
on.  The second trial was also unsuccessful, indicating that an error had most likely 
been made in previous steps of the experiment.  The experiment was performed 
again up until the preparation and gel purification of the insert and vector.   
3.3     Mini-preps From Colonies for MEF2-En Insert and pShuttle-CMV Vector 
     In order to achieve high expression of the dominant negative MEF2, this 
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construct also has to be cloned in an adenovirus.  The restriction enzyme digestion, 
ligation, and transformation was performed for this adenoviral vector, and from the 
transformation 25 colonies were selected for mini-preps used.  Colonies 4-9 were 
selected and mini-preps were made for each.  The mini-preps were double digested 
with HindIII and EcoRV and the products were run on a 0.8% agarose gel to 
ensure that the insertion was successful.  Three bands were expected; ~7.5 kb, ~0.9 
kb, and ~0.5 kb.  The mini-preps and digestion results for colonies 4 and 5 were 
inconclusive because the gel was not run for long enough.  The digestion of the 
mini-preps created from colonies 6 and 7 were unsuccessful due to a non-
functioning Not1 enzyme.  The mini-preps and restriction enzyme digestion of 
colonies 8 and 9 appeared to display bands that indicated a successful insertion of 
the MEF2-En insert into the pShuttle-CMV vector.   
3.4     Future Directions 
     More steps must be taken in order to create the desired shRNA resistant 
MEF2A overexpression vector as well as the dominant negative MEF2.  For the 
shRNA resistant over expression vector, the gel purified products from the 
successful restriction enzyme digestions of the insert and vector will be used in a 
ligation reaction and transformed into DH5α cells and plated on LB agar 
containing Ampicillin.  Some of the resulting colonies will be selected to create 
mini-preps of the desired plasmid, and an agarose gel will be run to make sure that 
the insertion was successful.  Once the appropriate mini-preps for both the 
dominant negative form of MEF2 and shRNA resistant form of MEF2A are 
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created, the plasmids will be transformed into cells so as to amplify and generate a 
stock of the adenoviruses.   
     The shRNA resistant over expression vector will be used in rescue experiments 
in order to demonstrate the specificity of the shRNA method used to knockdown 
the MEF2A in previous experiments and to ensure that the shRNA used does not 
have any targets other than the desired MEF2A that would create the observed 
phenotypes.  The dominant negative form of MEF2 can be used to transform into 
cells so as to knock out the entire MEF2 family of transcription factors in cells to 
determine the resulting phenotype, which can be used as a comparison to methods 
that knock down each isoform individually.     
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